<DOC>
	<DOC>NCT02219191</DOC>
	<brief_summary>To evaluate the Effect of Puerarin tablets versus statins in treating metabolism syndrome in patients with chronic rheumatic diseases</brief_summary>
	<brief_title>Puerarin Versus Atorvastatin in Treating Metabolism Syndrome in Patients With Chronic Rheumatic Diseases</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Collagen Diseases</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Puerarin</mesh_term>
	<mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
	<criteria>patients with a definite diagnose with rheumatic disease patients with metabolic Syndrome without conflict to the written, informed consent signed prior to the enrollment no severe hepatic or renal disorders no known carotid artery stenosis no coagulation disorders no hypertension being in pregnancy, lactation period or under a pregnancy plan being allergic to the test drug not compatible for the trial medication without full legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Puerarin tablet</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>metabolism syndrome</keyword>
</DOC>